222 related articles for article (PubMed ID: 30468032)
1. Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea.
Hur G; Song MS; Sohn S; Lee HD; Kim GB; Cho HJ; Yoon KL; Joo CU; Hyun MC; Kim CH
Korean Circ J; 2019 Feb; 49(2):183-191. PubMed ID: 30468032
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin for the treatment of Kawasaki disease.
Broderick C; Kobayashi S; Suto M; Ito S; Kobayashi T
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014884. PubMed ID: 36695415
[TBL] [Abstract][Full Text] [Related]
3. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
[TBL] [Abstract][Full Text] [Related]
4. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC; Jain S; Tremoulet AH; Kim KK; Burns JC; ; Anand V; Anderson M; Ang J; Ansusinha E; Arditi M; Ashouri N; Bartlett A; Chatterjee A; DeBiasi R; Dekker C; DeZure C; Didion L; Dominguez S; El Feghaly R; Erdem G; Halasa N; Harahsheh A; Jackson MA; Jaggi P; Jain S; Jone PN; Kaushik N; Kurio G; Lillian A; Lloyd D; Manaloor J; McNelis A; Michalik DE; Newburger J; Newcomer C; Perkins T; Portman M; Romero J; Ronis T; Rowley A; Schneider K; Schuster J; Tejtel SKS; Sharma K; Simonsen K; Szmuszkovicz J; Truong D; Wood J; Yeh S
Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
[TBL] [Abstract][Full Text] [Related]
5. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
Miyata K; Bainto EV; Sun X; Jain S; Dummer KB; Burns JC; Tremoulet AH
Arch Dis Child; 2023 Oct; 108(10):833-838. PubMed ID: 37258054
[TBL] [Abstract][Full Text] [Related]
6. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis.
Dionne A; Burns JC; Dahdah N; Tremoulet AH; Gauvreau K; de Ferranti SD; Baker AL; Son MB; Gould P; Fournier A; Newburger JW; Friedman KG
Pediatrics; 2019 Jun; 143(6):. PubMed ID: 31048414
[TBL] [Abstract][Full Text] [Related]
7. [Retrospective analysis of infliximab in the treatment of Kawasaki disease].
Xie LP; Zhao L; Chu C; He L; Liang XC; Sun SN; Zhao QM; Wang F; Cao YY; Lin YX; Zeng ZQ; Wu L; Huang GY; Liu F
Zhonghua Er Ke Za Zhi; 2022 Jan; 60(1):14-19. PubMed ID: 34986617
[No Abstract] [Full Text] [Related]
8. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL; Zhao SL
Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
[TBL] [Abstract][Full Text] [Related]
9. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
Wang L; He M; Wang W; Li S; Zhao G
Eur J Pediatr; 2024 Apr; 183(4):1765-1776. PubMed ID: 38240765
[TBL] [Abstract][Full Text] [Related]
11. Relationship between post-IVIG IgG levels and clinical outcomes in Kawasaki disease patients: new insight into the mechanism of action of IVIG.
Goto R; Inuzuka R; Shindo T; Namai Y; Oda Y; Harita Y; Oka A
Clin Rheumatol; 2020 Dec; 39(12):3747-3755. PubMed ID: 32458247
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
Iio K; Morikawa Y; Miyata K; Kaneko T; Misawa M; Yamagishi H; Miura M
J Pediatr; 2022 Jan; 240():158-163.e4. PubMed ID: 34461064
[TBL] [Abstract][Full Text] [Related]
13. Treatment of immunoglobulin-resistant kawasaki disease: a Bayesian network meta-analysis of different regimens.
Pan Y; Fan Q; Hu L
Front Pediatr; 2023; 11():1149519. PubMed ID: 37520059
[TBL] [Abstract][Full Text] [Related]
14. Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.
Sakai H; Iwashima S; Sano S; Akiyama N; Nagata E; Harazaki M; Fukuoka T
Clin Drug Investig; 2021 Jan; 41(1):77-88. PubMed ID: 33341911
[TBL] [Abstract][Full Text] [Related]
15. Effective infliximab therapy for the early regression of coronary artery aneurysm in Kawasaki disease.
Nagatomo Y; Muneuchi J; Nakashima Y; Nanishi E; Shirozu H; Watanabe M; Uike K; Nagata H; Hirata Y; Yamamura K; Takahashi Y; Okada S; Suzuki Y; Hasegawa S; Ohga S
Int J Cardiol; 2018 Nov; 271():317-321. PubMed ID: 30144998
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Fever in Children After Primary Treatment for Kawasaki Disease.
Jaggi P; Wang W; Dvorchik I; Printz B; Berry E; Kovalchin JP; Texter K; Ramilo O; Burns JC; Tremoulet AH
Pediatr Infect Dis J; 2015 Dec; 34(12):1315-8. PubMed ID: 26353031
[TBL] [Abstract][Full Text] [Related]
17. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
[TBL] [Abstract][Full Text] [Related]
18. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
Burns JC; Best BM; Mejias A; Mahony L; Fixler DE; Jafri HS; Melish ME; Jackson MA; Asmar BI; Lang DJ; Connor JD; Capparelli EV; Keen ML; Mamun K; Keenan GF; Ramilo O
J Pediatr; 2008 Dec; 153(6):833-8. PubMed ID: 18672254
[TBL] [Abstract][Full Text] [Related]
19. Association of Acute Anti-inflammatory Treatment With Medium-term Outcomes for Coronary Artery Aneurysms in Kawasaki Disease.
Friedman KG; McCrindle BW; Runeckles K; Dahdah N; Harahsheh AS; Khoury M; Lang S; Manlhiot C; Tremoulet AH; Raghuveer G; Selamet Tierney ES; Jone PN; Li JS; Szmuszkovicz JR; Norozi K; Jain SS; Yetman AT; Newburger JW;
CJC Pediatr Congenit Heart Dis; 2022 Aug; 1(4):174-183. PubMed ID: 37969928
[TBL] [Abstract][Full Text] [Related]
20. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
